98% of hospital inpatients undergo some form of diagnostic testing.1 Diagnostic tests for blood culture, blood chemistry and urine affect nearly every patient in your facility. And while ensuring patient care is your primary priority, you may also face other challenges such as complex tests, suboptimal workflows, preanalytical errors and staffing shortages. All such statements are based upon current expectations of BD and involve a number of business risks and uncertainties. Actual Betinwin Casino results could vary materially from anticipated results described, implied or projected in any forward-looking statement.
Enabling you to advance patient care at each step
By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. For more information on BD, please visit bd.com or connect with us on LinkedIn at /company/bd1/, X (formerly Twitter) @BDandCo or Instagram @becton_dickinson. BD is one of the largest global medical technology companies in the world and is advancing the world of healthTM by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of healthcare by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for healthcare providers.
Investors
1987 BD built a plant to manufacture diagnostic products in Fukushima, Japan. 2022 BD becomes the first company to combine flow cytometry with fluorescence imaging and image-based decisioning to sort individual cells based on visual details of the cell at exceptionally high speed (15,000 cells per second). 1 Reflects comparable FY24 revenue, adjusted for a full year of Advanced Patient Monitoring revenue generated during Edwards Lifesciences’ ownership. Please be aware of potentially fraudulent job postings on other websites or suspicious recruiting email or text messages that attempt to collect your confidential information.
The BD COR™ System uses multiplex PCR assay design and requires less than 1 hour of daily hands-on time for the full BD COR™ system workflow and only 2 interactions. In connection with today’s announcement, the company has decided to postpone its Investor Day, previously scheduled for February 26, 2025, to allow BD to focus on the transaction. The company expects to provide a comprehensive update on strategy and outlook in the future closer to the separation. BD’s board of directors is committed to exploring all opportunities to execute the separation in a manner that maximizes shareholder value, including possible options such as a Reverse Morris Trust, sale, spin-off or other transaction.
All content, including text, graphics, images and information etc., contained in or available through this literature is for general information purposes only. For diagnosis or treatment of any medical condition, please consult your physician/doctor. Becton Dickinson India Private Limited and or its affiliates, its employees are not liable for any damages/claims to any person in any manner whatsoever. 1913 BD merged with Oscar O.R. Schwidetzky’s surgical import company, bringing his Asepto™ bulb syringe along with helping to develop the American-made ACE® bandage. 1981 A new plant is built in Plymouth, England to manufacture BD Vacutainer® system products and serve a growing European market.
A bloodstream infection (BSI) can lead to a dysregulated immune response if untreated. To make substantial improvements to BSI testing, consider the entire diagnostic pathway – from blood culture collection to result. It has advanced fluorescence detection technology, exceptional media performance and instrument reliability—adding vial-activated workflow, advanced ergonomics, blood culture observation and customer-focused data management. The easy-to-use workflow comes in a compact, modular design, which can be adapted to multiple space- and time-saving configurations for your laboratory staff. From collecting specimens to reporting results, the diagnostic pathway has multiple points, each with the potential to optimize efficiencies and advance the quality of patient care. BD offers a comprehensive portfolio of integrated solutions designed to help your facility elevate the patient experience and position your lab as a vital resource, rather than a necessary cost center.
